Sickle-Cell Anemia: Molecular and Cellular Bases of Therapeutic Approaches

Abstract
(Third of Three Parts)Evaluation of New TherapiesTo facilitate the application of the previously discussed assays of gelation, sickling and rheology to new drugs, the Sickle Cell Disease Branch of the National Heart, Lung, and Blood Institute is establishing a laboratory and an advisory policy board to evaluate the efficacy of potential anti-sickling agents.242 This step is necessary because few laboratories have sufficient scientific and financial resources to evaluate potential drugs with a wide spectrum of technics. As a bare minimum, putative agents should be tested for their ability to inhibit cell sickling at a low oxygen tension, to . . .

This publication has 65 references indexed in Scilit: